ONO-4685
- Generic Name
- ONO-4685
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT06547528
- Locations
- π―π΅
Aichi Cancer Center Hospital, Nagoya-shi, Aichi, Japan
π―π΅Akita University Hospital, Akita-shi, Akita, Japan
π―π΅National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 33
- Registration Number
- NCT05332704
- Locations
- π²π©
Arensia Exploratory Medicine Phase 1 Unit, Chisinau, Moldova, Republic of
π·π΄Arensia Exploratory Medicine, Bucharest, Romania
π¬π§Medicines Evaluation Unit, Manchester, United Kingdom
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 217
- Registration Number
- NCT05079282
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈUniversity of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath